AndrodiasGLünemannJDMaillartE, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain. Epub ahead of print 21 December 2024. DOI: 10.1093/brain/awae409.
2.
DemuthSCollonguesNAudoinB, et al. Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder. Neurology2023; 101(4): e438–e450.
3.
DinotoACacciaguerraLVorasootN, et al. Clinical features and factors associated with outcome in late adult-onset myelin oligodendrocyte glycoprotein antibody-associated disease. Neurology2025.
KangYRJuHKimKH, et al. Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler2025.
6.
DeschampsRGuillaumeJCironJ, et al. Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: The MOGADOR2 study. Neurology2024; 103(3): e209624.
7.
KwonYNKimBKimJ-S, et al. Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol2024; 81(10): 1073–1084.
8.
MarignierRVillacieros-ÁlvarezJEspejoC, et al. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: The MULTIMOGAD study. J Neurol Neurosurg Psychiatr. Epub ahead of print 12 February 2025. DOI: 10.1136/jnnp-2024-335137.
9.
El HajjARuizAGavoilleA, et al. MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD. J Neurol Neurosurg Psychiatr. Epub ahead of print 28 March 2025. DOI: 10.1136/jnnp-2024-335579.
